Assessment  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
relationship  ||| S:18 E:31 ||| NN
between  ||| S:31 E:39 ||| IN
Helicobacter  ||| S:39 E:52 ||| NNP
pylori  ||| S:52 E:59 ||| JJ
infection ||| S:59 E:68 ||| NN
,  ||| S:68 E:70 ||| ,
endoscopic  ||| S:70 E:81 ||| JJ
appearance  ||| S:81 E:92 ||| NN
and  ||| S:92 E:96 ||| CC
histological  ||| S:96 E:109 ||| JJ
changes  ||| S:109 E:117 ||| NNS
of  ||| S:117 E:120 ||| IN
the  ||| S:120 E:124 ||| DT
gastric  ||| S:124 E:132 ||| JJ
mucosa  ||| S:132 E:139 ||| NN
in  ||| S:139 E:142 ||| IN
children  ||| S:142 E:151 ||| NNS
with  ||| S:151 E:156 ||| IN
gastritis  ||| S:156 E:166 ||| NNS
( ||| S:166 E:167 ||| -LRB-
a  ||| S:167 E:169 ||| DT
single  ||| S:169 E:176 ||| JJ
center  ||| S:176 E:183 ||| NN
experience ||| S:183 E:193 ||| NN
)  ||| S:193 E:195 ||| -RRB-
Helicobacter  ||| S:195 E:208 ||| NNP
pylori  ||| S:208 E:215 ||| JJ
infection  ||| S:215 E:225 ||| NN
is  ||| S:225 E:228 ||| VBZ
an  ||| S:228 E:231 ||| DT
important  ||| S:231 E:241 ||| JJ
cause  ||| S:241 E:247 ||| NN
of  ||| S:247 E:250 ||| IN
gastritis  ||| S:250 E:260 ||| NN
in  ||| S:260 E:263 ||| IN
childhood ||| S:263 E:272 ||| NN
,  ||| S:272 E:274 ||| ,
its  ||| S:274 E:278 ||| PRP$
role  ||| S:278 E:283 ||| NN
in  ||| S:283 E:286 ||| IN
the  ||| S:286 E:290 ||| DT
pathogenesis  ||| S:290 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
peptic  ||| S:306 E:313 ||| JJ
ulcer  ||| S:313 E:319 ||| JJ
disease  ||| S:319 E:327 ||| NN
in  ||| S:327 E:330 ||| IN
adults  ||| S:330 E:337 ||| NNS
and  ||| S:337 E:341 ||| CC
children  ||| S:341 E:350 ||| NNS
being  ||| S:350 E:356 ||| VBG
generally  ||| S:356 E:366 ||| RB
known ||| S:366 E:371 ||| VBN
.  ||| S:371 E:373 ||| .
In  ||| S:373 E:376 ||| IN
some  ||| S:376 E:381 ||| DT
cases ||| S:381 E:386 ||| NNS
,  ||| S:386 E:388 ||| ,
there  ||| S:388 E:394 ||| EX
are  ||| S:394 E:398 ||| VBP
therapeutic  ||| S:398 E:410 ||| JJ
management  ||| S:410 E:421 ||| NN
issues ||| S:421 E:427 ||| NNS
,  ||| S:427 E:429 ||| ,
because  ||| S:429 E:437 ||| IN
they  ||| S:437 E:442 ||| PRP
do  ||| S:442 E:445 ||| VBP
not  ||| S:445 E:449 ||| RB
heal  ||| S:449 E:454 ||| VB
or  ||| S:454 E:457 ||| CC
they  ||| S:457 E:462 ||| PRP
often  ||| S:462 E:468 ||| RB
relapse ||| S:468 E:475 ||| JJ
,  ||| S:475 E:477 ||| ,
although  ||| S:477 E:486 ||| IN
treatment  ||| S:486 E:496 ||| NN
regimens  ||| S:496 E:505 ||| NNS
are  ||| S:505 E:509 ||| VBP
applied  ||| S:509 E:517 ||| VBN
as  ||| S:517 E:520 ||| RB
recommended ||| S:520 E:531 ||| VBN
.  ||| S:531 E:533 ||| .
Our  ||| S:533 E:537 ||| PRP$
aim  ||| S:537 E:541 ||| NN
was  ||| S:541 E:545 ||| VBD
to  ||| S:545 E:548 ||| TO
analyze  ||| S:548 E:556 ||| VB
the  ||| S:556 E:560 ||| DT
relationship  ||| S:560 E:573 ||| NN
between  ||| S:573 E:581 ||| IN
endoscopic  ||| S:581 E:592 ||| JJ
appearance  ||| S:592 E:603 ||| NN
and  ||| S:603 E:607 ||| CC
histological  ||| S:607 E:620 ||| JJ
changes  ||| S:620 E:628 ||| NNS
of  ||| S:628 E:631 ||| IN
the  ||| S:631 E:635 ||| DT
gastric  ||| S:635 E:643 ||| JJ
mucosa  ||| S:643 E:650 ||| NN
in  ||| S:650 E:653 ||| IN
children  ||| S:653 E:662 ||| NNS
with  ||| S:662 E:667 ||| IN
gastritis  ||| S:667 E:677 ||| VBG
associated  ||| S:677 E:688 ||| VBN
with  ||| S:688 E:693 ||| IN
H.  ||| S:693 E:696 ||| NNP
pylori  ||| S:696 E:703 ||| JJ
infection ||| S:703 E:712 ||| NN
,  ||| S:712 E:714 ||| ,
in  ||| S:714 E:717 ||| IN
which  ||| S:717 E:723 ||| WDT
persistent  ||| S:723 E:734 ||| JJ
infection  ||| S:734 E:744 ||| NN
after  ||| S:744 E:750 ||| IN
treatment  ||| S:750 E:760 ||| NN
was  ||| S:760 E:764 ||| VBD
found ||| S:764 E:769 ||| VBN
.  ||| S:769 E:771 ||| .
It  ||| S:771 E:774 ||| PRP
was  ||| S:774 E:778 ||| VBD
a  ||| S:778 E:780 ||| DT
prospective  ||| S:780 E:792 ||| JJ
study  ||| S:792 E:798 ||| NN
on  ||| S:798 E:801 ||| IN
1332  ||| S:801 E:806 ||| CD
children  ||| S:806 E:815 ||| NNS
assessed  ||| S:815 E:824 ||| VBN
in  ||| S:824 E:827 ||| IN
our  ||| S:827 E:831 ||| PRP$
Service  ||| S:831 E:839 ||| NNP
( ||| S:839 E:840 ||| -LRB-
Ist  ||| S:840 E:844 ||| NNP
Pediatric  ||| S:844 E:854 ||| NNP
Clinic ||| S:854 E:860 ||| NNP
,  ||| S:860 E:862 ||| ,
Tirgu  ||| S:862 E:868 ||| NNP
Mures ||| S:868 E:873 ||| NNP
,  ||| S:873 E:875 ||| ,
Romania ||| S:875 E:882 ||| NNP
) ||| S:882 E:883 ||| -RRB-
,  ||| S:883 E:885 ||| ,
between  ||| S:885 E:893 ||| IN
January  ||| S:893 E:901 ||| NNP
2008  ||| S:901 E:906 ||| CD
and  ||| S:906 E:910 ||| CC
January  ||| S:910 E:918 ||| NNP
2013 ||| S:918 E:922 ||| CD
,  ||| S:922 E:924 ||| ,
for  ||| S:924 E:928 ||| IN
gastritis  ||| S:928 E:938 ||| NN
with  ||| S:938 E:943 ||| IN
various  ||| S:943 E:951 ||| JJ
etiologies ||| S:951 E:961 ||| NN
.  ||| S:961 E:963 ||| .
There  ||| S:963 E:969 ||| EX
were  ||| S:969 E:974 ||| VBD
609  ||| S:974 E:978 ||| CD
cases  ||| S:978 E:984 ||| NNS
of  ||| S:984 E:987 ||| IN
gastritis-associated  ||| S:987 E:1008 ||| JJ
with  ||| S:1008 E:1013 ||| IN
H.  ||| S:1013 E:1016 ||| NNP
pylori  ||| S:1016 E:1023 ||| JJ
infection ||| S:1023 E:1032 ||| NN
.  ||| S:1032 E:1034 ||| .
The  ||| S:1034 E:1038 ||| DT
average  ||| S:1038 E:1046 ||| JJ
age  ||| S:1046 E:1050 ||| NN
of  ||| S:1050 E:1053 ||| IN
patients  ||| S:1053 E:1062 ||| NNS
was  ||| S:1062 E:1066 ||| VBD
13.21  ||| S:1066 E:1072 ||| CD
years ||| S:1072 E:1077 ||| NNS
;  ||| S:1077 E:1079 ||| :
the  ||| S:1079 E:1083 ||| DT
higher  ||| S:1083 E:1090 ||| JJR
incidence  ||| S:1090 E:1100 ||| NN
was  ||| S:1100 E:1104 ||| VBD
noted  ||| S:1104 E:1110 ||| VBN
in  ||| S:1110 E:1113 ||| IN
13-18-year-old  ||| S:1113 E:1128 ||| CD
group ||| S:1128 E:1133 ||| NN
,  ||| S:1133 E:1135 ||| ,
female  ||| S:1135 E:1142 ||| JJ
gender  ||| S:1142 E:1149 ||| NN
and  ||| S:1149 E:1153 ||| CC
rural  ||| S:1153 E:1159 ||| JJ
areas  ||| S:1159 E:1165 ||| NNS
provenience ||| S:1165 E:1176 ||| VBP
;  ||| S:1176 E:1178 ||| :
a  ||| S:1178 E:1180 ||| DT
number  ||| S:1180 E:1187 ||| NN
of  ||| S:1187 E:1190 ||| IN
544  ||| S:1190 E:1194 ||| CD
patients  ||| S:1194 E:1203 ||| NNS
diagnosed  ||| S:1203 E:1213 ||| VBN
with  ||| S:1213 E:1218 ||| IN
gastritis  ||| S:1218 E:1228 ||| NN
with  ||| S:1228 E:1233 ||| IN
H.  ||| S:1233 E:1236 ||| NNP
pylori  ||| S:1236 E:1243 ||| NN
were  ||| S:1243 E:1248 ||| VBD
reassessed  ||| S:1248 E:1259 ||| VBN
subsequently ||| S:1259 E:1271 ||| RB
;  ||| S:1271 E:1273 ||| :
after  ||| S:1273 E:1279 ||| IN
treatment ||| S:1279 E:1288 ||| NN
,  ||| S:1288 E:1290 ||| ,
gastritis  ||| S:1290 E:1300 ||| NN
has  ||| S:1300 E:1304 ||| VBZ
healed  ||| S:1304 E:1311 ||| VBN
and  ||| S:1311 E:1315 ||| CC
the  ||| S:1315 E:1319 ||| DT
infection  ||| S:1319 E:1329 ||| NN
was  ||| S:1329 E:1333 ||| VBD
eradicated  ||| S:1333 E:1344 ||| VBN
in  ||| S:1344 E:1347 ||| IN
88.23 ||| S:1347 E:1352 ||| CD
%  ||| S:1352 E:1354 ||| NN
cases  ||| S:1354 E:1360 ||| NNS
after  ||| S:1360 E:1366 ||| IN
a  ||| S:1366 E:1368 ||| DT
month ||| S:1368 E:1373 ||| NN
,  ||| S:1373 E:1375 ||| ,
while  ||| S:1375 E:1381 ||| IN
in  ||| S:1381 E:1384 ||| IN
64  ||| S:1384 E:1387 ||| CD
patients  ||| S:1387 E:1396 ||| NNS
infection  ||| S:1396 E:1406 ||| NN
persisted ||| S:1406 E:1415 ||| VBD
.  ||| S:1415 E:1417 ||| .
After  ||| S:1417 E:1423 ||| IN
a  ||| S:1423 E:1425 ||| DT
second  ||| S:1425 E:1432 ||| JJ
regimen ||| S:1432 E:1439 ||| NN
,  ||| S:1439 E:1441 ||| ,
endoscopic-histological  ||| S:1441 E:1465 ||| JJ
modifications  ||| S:1465 E:1479 ||| NNS
persisted  ||| S:1479 E:1489 ||| VBD
in  ||| S:1489 E:1492 ||| IN
31  ||| S:1492 E:1495 ||| CD
( ||| S:1495 E:1496 ||| -LRB-
5.69 ||| S:1496 E:1500 ||| NNP
% ||| S:1500 E:1501 ||| NN
)  ||| S:1501 E:1503 ||| -RRB-
cases ||| S:1503 E:1508 ||| NNS
;  ||| S:1508 E:1510 ||| :
1.28 ||| S:1510 E:1514 ||| CD
%  ||| S:1514 E:1516 ||| NN
cases  ||| S:1516 E:1522 ||| NNS
remained  ||| S:1522 E:1531 ||| VBD
positive  ||| S:1531 E:1540 ||| JJ
for  ||| S:1540 E:1544 ||| IN
longer ||| S:1544 E:1550 ||| JJR
.  ||| S:1550 E:1552 ||| .
H.  ||| S:1552 E:1555 ||| NNP
pylori  ||| S:1555 E:1562 ||| JJ
infection  ||| S:1562 E:1572 ||| NN
was  ||| S:1572 E:1576 ||| VBD
associated  ||| S:1576 E:1587 ||| VBN
with  ||| S:1587 E:1592 ||| IN
high  ||| S:1592 E:1597 ||| JJ
age  ||| S:1597 E:1601 ||| NN
group ||| S:1601 E:1606 ||| NN
,  ||| S:1606 E:1608 ||| ,
as  ||| S:1608 E:1611 ||| RB
well  ||| S:1611 E:1616 ||| RB
as  ||| S:1616 E:1619 ||| RB
with  ||| S:1619 E:1624 ||| IN
endoscopic  ||| S:1624 E:1635 ||| JJ
modifications ||| S:1635 E:1648 ||| NNS
;  ||| S:1648 E:1650 ||| :
also ||| S:1650 E:1654 ||| RB
,  ||| S:1654 E:1656 ||| ,
the  ||| S:1656 E:1660 ||| DT
presence  ||| S:1660 E:1669 ||| NN
of  ||| S:1669 E:1672 ||| IN
H.  ||| S:1672 E:1675 ||| NNP
pylori  ||| S:1675 E:1682 ||| NN
was  ||| S:1682 E:1686 ||| VBD
correlated  ||| S:1686 E:1697 ||| VBN
with  ||| S:1697 E:1702 ||| IN
histopathologic  ||| S:1702 E:1718 ||| JJ
diagnostic ||| S:1718 E:1728 ||| NN
.  ||| S:1728 E:1730 ||| .
We  ||| S:1730 E:1733 ||| PRP
try  ||| S:1733 E:1737 ||| VBP
to  ||| S:1737 E:1740 ||| TO
emphasize  ||| S:1740 E:1750 ||| VB
the  ||| S:1750 E:1754 ||| DT
importance  ||| S:1754 E:1765 ||| NN
of  ||| S:1765 E:1768 ||| IN
assessing  ||| S:1768 E:1778 ||| VBG
bacterial  ||| S:1778 E:1788 ||| JJ
resistance  ||| S:1788 E:1799 ||| NN
to  ||| S:1799 E:1802 ||| TO
antibiotics ||| S:1802 E:1813 ||| VB
,  ||| S:1813 E:1815 ||| ,
studying  ||| S:1815 E:1824 ||| VBG
of  ||| S:1824 E:1827 ||| IN
bacterial  ||| S:1827 E:1837 ||| JJ
genome  ||| S:1837 E:1844 ||| NN
and  ||| S:1844 E:1848 ||| CC
genetic  ||| S:1848 E:1856 ||| JJ
susceptibility  ||| S:1856 E:1871 ||| NN
of  ||| S:1871 E:1874 ||| IN
human  ||| S:1874 E:1880 ||| JJ
subjects ||| S:1880 E:1888 ||| NNS
.  ||| S:1888 E:1890 ||| .
